Merck KGaA (MKGAY)

Other OTC - Other OTC Delayed Price. Currency in USD
36.31-0.13 (-0.36%)
At close: 2:31 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close36.44
Bid0.00 x
Ask0.00 x
Day's Range36.24 - 36.42
52wk Range35.84 - 37.16
1y Target EstN/A
Market Cap47.41B
P/E Ratio (ttm)30.56
Avg Vol (3m)3,443
Dividend & Yield0.40 (1.10%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Merck KGaA :MKGAY-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016
    Capital Cube15 days ago

    Merck KGaA :MKGAY-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016

    Categories: Yahoo Finance Click here to see latest analysis Merck KGaA reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Merck KGaA – Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., Amgen Inc., Abbott Laboratories, Biogen Inc. and ARIAD Pharmaceuticals, Inc. (BMY-US, PFE-US, MRK-US, AMGN-US, ABT-US, ... Read more (Read more...)

  • PR Newswire2 months ago

    Juniper Pharmaceuticals Announces that Merck KGaA, Darmstadt, Germany, has Obtained Regulatory Approval for OneCrinone® in Japan

    BOSTON, July 5, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that for the Japanese market Merck KGaA, Darmstadt, Germany (XETRA:MRK.DE), acting through its biopharma business, has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for OneCrinone® 90 mg (progesterone) for the indication of luteal phase supplementation in assisted reproductive treatment. "This approval further expands the global Crinone® progesterone gel franchise into the world's' third largest pharmaceutical market, giving women and couples struggling with infertility in Japan a new, patient-friendly therapeutic option for luteal phase support," said Frank Condella, Juniper's CEO. Merck KGaA, Darmstadt, Germany, has worldwide marketing rights to Crinone® except in the United States, where Crinone® is marketed by Allergan, Inc. (AGN).  Outside the U.S., Merck KGaA, Darmstadt, Germany, holds the marketing authorization for Crinone® in over 90 countries.

  • PR Newswire2 months ago

    Merck KGaA, Darmstadt, Germany, Welcomes ZEISS and Hamilton Thorne as New Members of the Global Fertility Alliance

    Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced together with Illumina Inc., San Diego, US, and Genea Limited, Sydney, Australia, that the Global Fertility Alliance welcomed two new members. The alliance is a collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment (ART) laboratory.